FAQ on Clene's Upcoming FDA Meeting for CNM-Au8 Discussion

What is the purpose of Clene’s upcoming meeting with the FDA?

The meeting aims to discuss the development of Clene’s proprietary CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS), involving key FDA representatives and experts.

When is the meeting between Clene and the FDA scheduled to take place?

The in-person meeting is scheduled to occur before the end of November 2024.

Who will be attending the meeting from the FDA?

Attendees will include the FDA’s director of the Office on New Drugs, director of the Office of Neuroscience, the Division of Neurology 1 review team, and key opinion leaders in ALS, biostatistics, and biomarkers.

What is CNM-Au8?

CNM-Au8 is an investigational, first-in-class therapy by Clene that targets mitochondrial function and the NAD pathway to improve the survival and function of central nervous system cells, aiming to treat neurodegenerative diseases like ALS.

Where can I find more information about Clene and CNM-Au8?

More information is available on Clene’s website at www.Clene.com and the full press release can be viewed at https://ibn.fm/YtDp3.

What neurodegenerative diseases is Clene focusing on?

Clene is focused on treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis through improving mitochondrial health and protecting neuronal function.

How does CNM-Au8 work?

CNM-Au8 works by improving mitochondrial function and the NAD pathway while reducing oxidative stress, thereby enhancing the survival and function of central nervous system cells.

Where is Clene based?

Clene is headquartered in Salt Lake City, Utah, with research and development and manufacturing operations in Maryland.

Who can I contact for more information about Clene’s investor relations?

For investor relations, you can contact IBN (InvestorBrandNetwork) at Editor@InvestorBrandNetwork.com or visit their website at https://www.InvestorBrandNetwork.com.